SG10201912678QA - Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy - Google Patents

Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

Info

Publication number
SG10201912678QA
SG10201912678QA SG10201912678QA SG10201912678QA SG10201912678QA SG 10201912678Q A SG10201912678Q A SG 10201912678QA SG 10201912678Q A SG10201912678Q A SG 10201912678QA SG 10201912678Q A SG10201912678Q A SG 10201912678QA SG 10201912678Q A SG10201912678Q A SG 10201912678QA
Authority
SG
Singapore
Prior art keywords
therapy
disease
specific targets
enhanced efficacy
selecting neoepitopes
Prior art date
Application number
SG10201912678QA
Inventor
Arbel D Tadmor
Ugur Sahin
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of SG10201912678QA publication Critical patent/SG10201912678QA/en

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10Ploidy or copy number detection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
SG10201912678QA 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy SG10201912678QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016067348 2016-07-20

Publications (1)

Publication Number Publication Date
SG10201912678QA true SG10201912678QA (en) 2020-02-27

Family

ID=59399416

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201900132QA SG11201900132QA (en) 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
SG10201912678QA SG10201912678QA (en) 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201900132QA SG11201900132QA (en) 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

Country Status (22)

Country Link
US (1) US20190189241A1 (en)
EP (2) EP3967324A1 (en)
JP (2) JP7171543B2 (en)
KR (2) KR102516166B1 (en)
CN (2) CN109477149A (en)
AU (1) AU2017299162A1 (en)
BR (1) BR112018077122A8 (en)
CA (1) CA3031003A1 (en)
CY (1) CY1124551T1 (en)
DK (1) DK3488443T3 (en)
ES (1) ES2890424T3 (en)
HR (1) HRP20211443T1 (en)
HU (1) HUE056660T2 (en)
IL (2) IL311369A (en)
LT (1) LT3488443T (en)
MX (4) MX2019000733A (en)
PL (1) PL3488443T3 (en)
PT (1) PT3488443T (en)
RS (1) RS62390B1 (en)
SG (2) SG11201900132QA (en)
SI (1) SI3488443T1 (en)
WO (1) WO2018015433A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051252A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2019031939A2 (en) * 2017-08-10 2019-02-14 주식회사 굳티셀 Method for activating t cells for cancer treatment
SG11202002711WA (en) * 2017-10-12 2020-04-29 Nantomics Llc Cancer score for assessment and response prediction from biological fluids
CN109294983A (en) * 2018-09-30 2019-02-01 北京鼎成肽源生物技术有限公司 A kind of LFF2 cell
CN111402954B (en) * 2019-01-02 2023-07-21 中国人民解放军军事科学院军事医学研究院 Method for identifying and predicting human genes related to space radiation injury protection drug targets

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
ES2337207T3 (en) 2006-04-12 2010-04-21 Medical Research Council PROCEDURE TO DETERMINE THE NUMBER OF COPIES.
WO2009026432A1 (en) 2007-08-21 2009-02-26 Washington University Improved alzheimer's diagnosis
BRPI0816393A2 (en) 2007-09-07 2015-03-03 Fluidigm Corp METHOD FOR DETERMINING THE NUMBER OF COPIES REGARDING A TARGET POLINUCLEOTIDE SEQUENCE IN A GENOME OF AN INDIVIDUAL
KR102095670B1 (en) * 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 Compositions and methods of identifying tumor specific neoantigens
SI3892295T1 (en) * 2011-05-24 2023-09-29 BioNTech SE Individualized vaccines for cancer
KR102134932B1 (en) * 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 Cyclin a1 -targeted t-cell immunotherapy for cancer
US9569586B2 (en) * 2012-02-13 2017-02-14 Albert Rubben Algorithm for modification of somatic cancer evolution
AU2012376134B2 (en) 2012-04-05 2016-03-03 Bgi Genomics Co., Ltd. Method and system for detecting copy number variation
CN104662171B (en) * 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 Individualized cancer vaccine and adoptive immunity cell therapy
WO2014014497A1 (en) 2012-07-20 2014-01-23 Verinata Health, Inc. Detecting and classifying copy number variation in a cancer genome
CN105359151B (en) 2013-03-06 2019-04-05 生命科技股份有限公司 System and method for determining copy number variation
KR102341899B1 (en) * 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 Compositions and methods for personalized neoplasia vaccines
US20150331992A1 (en) * 2014-05-15 2015-11-19 Ramot At Tel-Aviv University Ltd. Cancer prognosis and therapy based on syntheic lethality
KR20240010089A (en) * 2015-10-12 2024-01-23 난토믹스, 엘엘씨 Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
PE20181535A1 (en) * 2015-12-16 2018-09-26 Gritstone Oncology Inc IDENTIFICATION, MANUFACTURE AND USE OF NEOANTIGEN
US20190247435A1 (en) * 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy

Also Published As

Publication number Publication date
MX2019000733A (en) 2019-05-02
EP3488443B1 (en) 2021-08-18
KR20230019223A (en) 2023-02-07
JP2019524106A (en) 2019-09-05
MX2023009369A (en) 2023-08-16
PL3488443T3 (en) 2021-12-20
IL311369A (en) 2024-05-01
HUE056660T2 (en) 2022-03-28
US20190189241A1 (en) 2019-06-20
KR102516166B1 (en) 2023-03-31
IL264203B1 (en) 2024-04-01
KR20190027832A (en) 2019-03-15
CN109477149A (en) 2019-03-15
PT3488443T (en) 2021-09-24
MX2023009371A (en) 2023-08-16
JP7171543B2 (en) 2022-11-15
JP2023009120A (en) 2023-01-19
BR112018077122A8 (en) 2023-01-31
IL264203A (en) 2019-02-28
HRP20211443T1 (en) 2021-12-24
CY1124551T1 (en) 2022-07-22
MX2023009370A (en) 2023-08-16
SG11201900132QA (en) 2019-02-27
WO2018015433A3 (en) 2018-03-01
RS62390B1 (en) 2021-10-29
SI3488443T1 (en) 2021-11-30
CN117757931A (en) 2024-03-26
BR112018077122A2 (en) 2019-04-30
EP3488443B8 (en) 2021-09-29
WO2018015433A2 (en) 2018-01-25
LT3488443T (en) 2021-10-25
ES2890424T3 (en) 2022-01-19
AU2017299162A1 (en) 2019-02-07
EP3967324A1 (en) 2022-03-16
DK3488443T3 (en) 2021-09-27
EP3488443A2 (en) 2019-05-29
CA3031003A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
IL255217B (en) Cancer neoepitopes
IL254705B (en) Combination therapy for cancer
IL259017A (en) Targeted cancer therapy
ZA201702382B (en) Combination therapy for cancer
HUE064857T2 (en) Combination therapy against cancer
HK1231381A1 (en) Combination therapy for cancer
IL264203A (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
IL246761A0 (en) Combination therapy for cancer
EP3256115A4 (en) Combination cancer therapy
GB201519734D0 (en) Cancer therapy
HK1254687A1 (en) Combination therapy for cancer
HRP20210383T8 (en) Combination therapy for cancer
GB201613172D0 (en) Combustion therapy
GB201511609D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy